Effects of Voriconazole Exposure on the Pharmacokinetics of Tacrolimus in Lung Transplantation Patients, Based on Therapeutic Drug Monitoring Data
- 17 May 2022
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 62 (10) , 1310-1320
Abstract
Tacrolimus and voriconazole are usually used simultaneously in lung transplantations. Voriconazole can increase tacrolimus concentrations by inhibiting the cytochrome P450 (CYP) enzyme, which poses a great challenge for dose adjustment. The aim of this study is to clarify the correlation between voriconazole exposure and tacrolimus trough concentrations (C0), and to establish a population pharmacokinetic model including voriconazole trough concentrations (VOZ) as a covariate for dose optimization. All data were retrospectively collected from lung transplantation patients who were subjected to therapeutic drug monitoring of tacrolimus and voriconazole. The correlation between C0 and VOZ or voriconazole daily doses was analyzed by Spearman's correlation. A total of 52 patients accounting for 351 pairs of tacrolimus and voriconazole trough concentrations were included. C0 and C0/daily dose of tacrolimus (DD) had a significant correlation with VOZ (P < .01) rather than voriconazole daily doses. A linear one‐compartment model with first‐order absorption and elimination was used as the basic model for population pharmacokinetic analysis. Body weight (WT), DD, VOZ, and hematocrit (HCT) were included as covariates in the final model. With the increase in voriconazole concentrations, the apparent total clearance (clearance/bioavailability, CL/F) of tacrolimus decreased significantly. The simulation results showed that the highest proportion of C0 within the target range can only reach <50% when the optimal initial drug regimen was given. Therefore, both tacrolimus and voriconazole concentrations need to be continuously monitored during treatments in lung transplantation patients, and the tacrolimus dose can be optimized according to VOZ based on the established pharmacokinetic model.Keywords
This publication has 22 references indexed in Scilit:
- Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical ReviewClinical Pharmacokinetics, 2015
- Prediction of Voriconazole Non-linear Pharmacokinetics Using a Paediatric Physiologically Based Pharmacokinetic Modelling ApproachClinical Pharmacokinetics, 2015
- Mold Infections in Lung Transplant RecipientsSeminars in Respiratory and Critical Care Medicine, 2013
- Quality of Life in Lung TransplantationSeminars in Respiratory and Critical Care Medicine, 2013
- Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: Results of a prospective, randomized international trial in lung transplantationThe Journal of Heart and Lung Transplantation, 2012
- Population Pharmacokinetic Modelling and Design of a Bayesian Estimator for Therapeutic Drug Monitoring of Tacrolimus in Lung TransplantationClinical Pharmacokinetics, 2012
- Voriconazole and itraconazole in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interactionClinical Transplantation, 2010
- Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patientsTransplant Infectious Disease, 2009
- Mechanism-Based Concepts of Size and Maturity in PharmacokineticsAnnual Review of Pharmacology and Toxicology, 2008
- Pharmacokinetic Study of Tacrolimus in Cystic Fibrosis and Non-Cystic Fibrosis Lung Transplant Patients and Design of Bayesian Estimators Using Limited Sampling StrategiesClinical Pharmacokinetics, 2005